Volume 4.30 | Aug 9

Prostate Cell News 4.30 August 9, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Marchantin M: A Novel Inhibitor of Proteasome Induces Autophagic Cell Death in Prostate Cancer Cells
Scientists demonstrated that marchantin M potently inhibited chymotrypsin-like and peptidyl-glutamyl peptide-hydrolyzing activities of 20S proteasome both in in vitro and intracellular systems and significantly induced the accumulation of polyubiquitinated proteins in prostate cancer cells. [Cell Death Dis] Full Article
Detect 7 times more prostate epithelial progenitors with ProstaCult
PUBLICATIONS (Ranked by impact factor of the journal)

IL-6 Sensitizes Prostate Cancer to the Antiproliferative Effect of IFNa2 through IRF9
To identify novel pathways that are triggered by interleukin (IL)-6, researchers performed a gene expression profiling of two prostate cancer (PCa) cell lines, LNCaP and MDA PCa 2b, treated with 5 ng/ml IL-6. Interferon regulatory factor (IRF)9 was identified as one of the most prevalent IL-6 regulated genes in both cell lines. [Endocr Relat Cancer] Abstract

The Tumor Suppressor miR-34c Targets MET in Prostate Cancer Cells
Scientists set out to characterize the mechanisms by which microRNA (miR)-34c deregulation contributes to prostate cancer progression. They confirmed the inhibitory effect of miR-34c on both MET transcript and protein levels. [Brit J Cancer] Abstract

Transcriptional Regulation of CXCR4 in Prostate Tumor Cells: Significance of TMPRSS2-ERG Fusions
The authors investigated molecular mechanisms of ERG-mediated CXCR4 promoter activation, phosphorylation of ERG by intracellular kinases and subsequent CXCR4 expression, as well as expression of ERG and CXCR4 in human prostate tumor tissues. [Mol Cancer Res] Abstract

Inhibition of Cell Adhesion by an Anti-Cadherin 11 Antibody Prevents Bone Metastasis
Downregulation of cadherin-11 inhibits interaction of prostate cancer (PCa) cells with osteoblasts in vitro and homing of PCa cells to bone in an animal model of metastasis. [Mol Cancer Res] Abstract

RhoGDIa Downregulates Androgen Receptor Signaling in Prostate Cancer Cells
Researchers examined the effect of GDP Dissociation Inhibitor alpha (GDIa) on androgen receptor (AR) signaling in prostate cancer cells. They identified GDIa as a negative regulator of AR signaling pathway. [Prostate] Abstract

Alpha-Tomatine Synergizes with Paclitaxel to Enhance Apoptosis of Androgen-Independent Human Prostate Cancer PC-3 Cells In Vitro and In Vivo
Combined treatment with a sub-toxic dose of a-tomatine and paclitaxel significantly decreased cell viability with concomitant increase in the percentage of apoptotic PC-3 cells. [Phytomedicine]
Abstract | Graphical Abstract

Glucose-Regulated Protein 78 Mediates Hormone-Independent Prostate Cancer Progression and Metastasis through Maspin and COX-2 Expression
Investigators found that the expression levels of glucose-regulated protein 78 were higher in PC-3 cells than in DU-145 cells. [Tumor Biol] Abstract

Chemokine Receptor Expression on Integrin-Mediated Stellate Projections of Prostate Cancer Cells in 3D Culture
Scientists report that CXCR7 and CXCR4 were co-expressed in LNCaP, DU145 and PC3 cell lines in 2D culture. When cultured in 3D using Matrigel, a marked up-regulation of both receptors was observed in PC3 cells. [Cytokine] Abstract

Reactive Oxygen Species Mediate Isoalantolactone-Induced Apoptosis in Human Prostate Cancer Cells
Researchers found that isoalantolactone inhibits growth of both androgen-sensitive as well as androgen-independent prostate cancer cells in a dose-dependent manner. [Molecules] Abstract | Full Article


The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer
As measured by overall survival, progression-free survival, prostate-specific antigen, and the objective response rate, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with metastatic castration-resistant prostate cancer who received subsequent docetaxel-based therapy. [Cancer] Abstract

Phase II Trial of Zoledronic Acid Combined with Androgen-Deprivation Therapy for Treatment-Naïve Prostate Cancer with Bone Metastasis
The authors conducted a Phase II study to investigate the benefits of combined zoledronic acid and androgen deprivation therapy in treatment-naïve prostate cancer with bone metastasis. [Int J Clin Oncol] Abstract

New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
Dietary Antioxidants and Prostate Cancer: A Review
The authors provide a systematic review of studies on prostate cancer and antioxidant intake from diet and supplements. Tea and coffee appear to offer protection against advanced prostate cancer. [Nutr Cancer] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
UCLA Prostate Cancer Research Program Receives $11.6 Million Federal Grant
UCLA’s Jonsson Comprehensive Cancer Center and the department of urology at the David Geffen School of Medicine at UCLA have been notified that their standing as a National Cancer Institute Specialized Program of Research Excellence site in prostate cancer has been renewed for another five years. [University of California Los Angeles] Press Release

Berg Partners with Department of Defense Research Center and Military Medical Foundation to Advance Prostate Cancer Research
Berg announced a new partnership with the U.S. Department of Defense under a Cooperative Research and Development Agreement with the Uniformed Services University of the Health Sciences’ Center for Prostate Disease Research and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to offer hope, and possibly one day a cure, for the 238,590 men diagnosed with prostate cancer each year. [PR Newswire Association LLC] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW World Conference on Regenerative Medicine
October 23-25, 2013
Leipzig, Germany

Visit our events page to see a complete list of events in the prostate cell community.
NEW Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Postdoctoral Position – Prostate Cancer (Tulane University)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Fellow – Steroid Receptor Signaling (Baylor College of Medicine)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Lead Research Technologist – Translational Prostate Cancer Research Program (Cleveland Clinic)

Project Scientist – Prostate Cancer Research (University of California at Los Angeles)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us